Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gonadorelin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR known ✓ | P30968 | 3/20 | 0.88 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.96 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.86 |
| ▸ | APLNR | P35414 | 3/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gonadorelin SCHEMBL29371269 | 1.00 | PTGS1 (0.96) | PTGS1GNRHRABCC2APLNR | |
| Gonadorelin SCHEMBL29351373 | 1.00 | PTGS1 (0.96) | PTGS1GNRHRABCC2APLNR | |
| Gonadorelin SCHEMBL20856309 | 0.99 | PTGS1 (0.94) | PTGS1GNRHRABCC2APLNR | |
| Gonadorelin SCHEMBL29359962 | 0.99 | PTGS1 (0.93) | PTGS1GNRHRABCC2APLNR | |
| Gonadorelin SCHEMBL20856308 | 0.98 | PTGS1 (0.93) | PTGS1GNRHRABCC2APLNR | |
| Triptorelin SCHEMBL30022783 | 0.98 | PTGS1 (1.00) | PTGS1GNRHRABCC2APLNR | |
| Triptorelin SCHEMBL29903080 | 0.98 | PTGS1 (1.00) | PTGS1GNRHRABCC2APLNR | |
| Triptorelin SCHEMBL19712233 | 0.98 | PTGS1 (1.00) | PTGS1GNRHRABCC2APLNR | |
| SCHEMBL29384641 | 0.97 | PTGS1 (0.90) | PTGS1GNRHRABCC2APLNR | |
| Fertirelin SCHEMBL31351846 | 0.97 | GNRHR (0.95) | PTGS1GNRHRABCC2APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 19116 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746850-A1 | EXTENDED RELEASE DRUG-LOADED MICROPARTICLES | Ferring BV (NL) | 2026-05-27 | — | — | EP | claimed |
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | BHAMIS RES LABORATORY PVT LTD (IN) | 2026-05-07 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| EP-4727979-A2 | COMPOSITIONS AND METHODS FOR TARGETING EXTRACELLULAR DNA | Caris Science, Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4729519-A1 | CRYSTAL FORM OF ENPP1 INHIBITOR | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2026-04-22 | — | — | EP | claimed |
| US-12533321-B2 | Polypeptide formulations for oral delivery | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2026-01-27 | — | — | US | claimed |
| US-20260014090-A1 | NANOPARTICLES FOR TARGETED NON-SURGICAL SPAYING AND NEUTERING | UNIV GEORGIA (US) | 2026-01-15 | — | — | US | claimed |
| EP-4642484-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| EP-4642492-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| US-20250332222-A1 | BATCH MANAGEMENT METHOD FOR IMPROVING FARROWING RATE OR NUMBER OF PIGLETS BORN ALIVE IN SWINE | UNIV CHINA AGRICULTURAL (CN) | 2025-10-30 | — | — | US | claimed |
| WO-1994003157-A1 | PHARMACEUTICAL COMPOSITIONS FOR TRANSMUCOSAL DELIVERY OF PEPTIDES | POLI INDUSTRIA CHIMICA S.P.A. (IT) | 1994-02-17 | — | — | WO | claimed |
| EP-0538443-A4 | METHODS AND FORMULATIONS FOR USE IN INHIBITING CONCEPTION AND IN TREATING BENIGN GYNECOLOGICAL DISORDERS | — | 1993-12-08 | — | — | EP | claimed |
| WO-1993015722-A1 | CONTROLLED DELIVERY OF PHARMACEUTICALS FROM PREFORMED POROUS MICROPARTICLES | SYNTEX (USA) INC. (US) | 1993-08-19 | — | — | WO | claimed |
| US-5211952-A | Drug delivery of gonadotropin hormone releasing hormones for time release | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1993-05-18 | — | — | US | claimed |
| EP-0538443-A1 | METHODS AND FORMULATIONS FOR USE IN INHIBITING CONCEPTION AND IN TREATING BENIGN GYNECOLOGICAL DISORDERS. | UNIV SOUTHERN CALIFORNIA (US) | 1993-04-28 | — | — | EP | claimed |
| US-5167616-A | Method of optimizing the transdermal flux | ALZA CORPORATION (US) | 1992-12-01 | — | — | US | claimed |
| WO-1992018107-A1 | METHODS AND FORMULATIONS FOR USE IN INHIBITING CONCEPTION AND IN TREATING BENIGN GYNECOLOGICAL DISORDERS | THE UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1992-10-29 | — | — | WO | claimed |
| WO-1991008795-A2 | IMPROVED IONTOPHORETIC DELIVERY METHOD | ALZA CORPORATION (US) | 1991-06-27 | — | — | WO | claimed |
| EP-0202569-A1 | Nose spray for combating male or female sterility | Oppermann, Dirck Dr. Med. (DE) | 1986-11-26 | — | — | EP | claimed |
| US-4136173-A | VEHICLES FOR OPHTHALMIC DRUGS | AMERICAN HOME PRODUCTS CORP. (US) | 1979-01-23 | — | — | US | claimed |